Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Birgit Geoerger

Showing results (1-10 of 179) with videos related to

Pageof 18
Sort By:
The Lancet. Oncology|March 6, 2020
Anti-PD-1 shows promise against advanced paediatric Hodgkin lymphoma - Author's replyBirgit Geoerger
Lancet (London, England)|November 20, 2012
Everolimus for astrocytomas in tuberous sclerosis complexBirgit Geoerger, Heike Blockus
Bulletin Du Cancer|May 21, 2011
[Indications and current development of new targeted therapies in pediatric oncology]Pierre Leblond, Birgit Geoerger
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2013
Is the European pediatric medicine regulation working for children and adolescents with cancer?Gilles Vassal, Birgit Geoerger, Bruce Morland
Cancer Discovery|November 2, 2021
Precision Cancer Medicine: Large Studies Indicate Steady ProgressAlexander Eggermont, Birgit Geoerger, Giuseppe Curigliano
Current Opinion in Pediatrics|December 1, 2017
Precision medicine in pediatric oncologySuzanne J Forrest, Birgit Geoerger, Katherine A Janeway
Clinical Trials (London, England)|September 21, 2019
Sequential or combined designs for Phase I/II clinical trials? A simulation studyCaroline Rossoni, Aurélie Bardet, Birgit Geoerger, et al.
Current Cancer Drug Targets|February 22, 2008
Small molecule tyrosine kinase inhibitors: potential role in pediatric malignant solid tumorsJochen Rössler, Birgit Geoerger, Melissa Taylor, et al.
Contemporary Clinical Trials|January 31, 2016
Innovations for phase I dose-finding designs in pediatric oncology clinical trialsAdelaide Doussau, Birgit Geoerger, Irene Jiménez, et al.
Expert Opinion on Investigational Drugs|May 18, 2010
New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near futureMelissa Taylor, Jochen Rössler, Birgit Geoerger, et al.
Pageof 18

Showing results (1-10 of 179) with videos related to

Sort By:
Pageof 18
The Lancet. Oncology|March 6, 2020
Anti-PD-1 shows promise against advanced paediatric Hodgkin lymphoma - Author's replyBirgit Geoerger
Lancet (London, England)|November 20, 2012
Everolimus for astrocytomas in tuberous sclerosis complexBirgit Geoerger, Heike Blockus
Bulletin Du Cancer|May 21, 2011
[Indications and current development of new targeted therapies in pediatric oncology]Pierre Leblond, Birgit Geoerger
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2013
Is the European pediatric medicine regulation working for children and adolescents with cancer?Gilles Vassal, Birgit Geoerger, Bruce Morland
Cancer Discovery|November 2, 2021
Precision Cancer Medicine: Large Studies Indicate Steady ProgressAlexander Eggermont, Birgit Geoerger, Giuseppe Curigliano
Current Opinion in Pediatrics|December 1, 2017
Precision medicine in pediatric oncologySuzanne J Forrest, Birgit Geoerger, Katherine A Janeway
Clinical Trials (London, England)|September 21, 2019
Sequential or combined designs for Phase I/II clinical trials? A simulation studyCaroline Rossoni, Aurélie Bardet, Birgit Geoerger, et al.
Current Cancer Drug Targets|February 22, 2008
Small molecule tyrosine kinase inhibitors: potential role in pediatric malignant solid tumorsJochen Rössler, Birgit Geoerger, Melissa Taylor, et al.
Contemporary Clinical Trials|January 31, 2016
Innovations for phase I dose-finding designs in pediatric oncology clinical trialsAdelaide Doussau, Birgit Geoerger, Irene Jiménez, et al.
Expert Opinion on Investigational Drugs|May 18, 2010
New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near futureMelissa Taylor, Jochen Rössler, Birgit Geoerger, et al.
Pageof 18